SEC Stock Data Quick Answer XBiotech Inc. reported R&D Expense of $47.39 million for fiscal year 2025. XBiotech Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $47.39M +25.5% 2024 $37.76M +14.9% 2023 $32.85M +4.1% 2022 $31.54M +11.6% 2021 $28.27M +196.7% 2020 $9.53M -60.5% 2019 $24.09M +53.2% 2018 $15.72M -40.5% 2017 $26.42M -37.8% 2016 … Read more
Quick Answer XBiotech Inc. reported Stockholders Equity of $140.35 million for fiscal year 2025. XBiotech Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $140.35M -23.0% 2024 $182.27M -16.7% 2023 $218.85M -9.0% 2022 $240.40M -10.8% 2021 $269.38M -22.7% 2020 $348.64M -53.9% 2019 $755.63M +1725.3% 2018 $41.40M -31.2% 2017 $60.16M +1.9% 2016 … Read more
Quick Answer XBiotech Inc. reported Cash and Equivalents of $125.55 million for fiscal year 2025. XBiotech Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $125.55M -27.3% 2024 $172.68M -13.7% 2023 $200.02M +27.2% 2022 $157.31M -33.6% 2021 $236.98M -0.2% 2020 $237.37M -66.8% 2019 $714.59M +4416.2% 2018 $15.82M -50.2% 2017 … Read more
Quick Answer XBiotech Inc. reported Total Assets of $150.08 million for fiscal year 2025. XBiotech Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $150.08M -24.6% 2024 $199.09M -12.1% 2023 $226.62M -7.9% 2022 $246.10M -10.6% 2021 $275.18M -22.2% 2020 $353.74M -56.7% 2019 $816.88M +1742.1% 2018 $44.34M -29.6% 2017 $62.97M -6.1% 2016 … Read more
Quick Answer XBiotech Inc. reported Diluted EPS of $0.81 per share (loss) for fiscal year 2023. XBiotech Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2023 -$0.81 +25.0% 2022 -$1.08 -86.2% 2021 -$0.58 -61.1% 2020 -$0.36 -102.5% 2019 $14.44 +2547.5% 2018 -$0.59 +37.9% 2017 -$0.95 — XBiotech Inc. showed an increase … Read more
Quick Answer XBiotech Inc. reported Net Income of -$45.54 million for fiscal year 2025. XBiotech Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$45.54M -18.2% 2024 -$38.53M -56.9% 2023 -$24.56M +25.4% 2022 -$32.90M -88.9% 2021 -$17.41M -55.2% 2020 -$11.22M -101.7% 2019 $668.63M +3263.2% 2018 -$21.14M +36.2% 2017 -$33.15M +37.2% 2016 … Read more
Quick Answer XBiotech Inc. reported Net Income of -$45.54 million for fiscal year 2025. XBiotech Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Net Income -$45.54M-18.2% -$38.53M-56.9% -$24.56M+25.4% -$32.90M-88.9% -$17.41M-55.2% -$11.22M-101.7% Diluted EPS — — -$0.81+25.0% -$1.08-86.2% -$0.58-61.1% -$0.36-102.5% Total Assets $150.08M-24.6% $199.09M-12.1% $226.62M-7.9% $246.10M-10.6% $275.18M-22.2% $353.74M-56.7% Cash and Equivalents … Read more
Quick Answer Xenetic Biosciences, Inc. reported Shares Outstanding of 2.29 million shares for fiscal year 2025. Xenetic Biosciences, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 2.29M +48.6% 2024 1.54M +0.1% 2023 1.54M +1.6% 2022 1.52M -88.7% 2021 13.44M +53.7% 2020 8.75M +44.2% 2019 6.07M -35.5% 2018 9.40M +7.9% 2017 … Read more
Quick Answer Xenetic Biosciences, Inc. reported Gross Profit of $0.00 for fiscal year 2014. Xenetic Biosciences, Inc. Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2014 $0.00 -100.0% 2013 $1.00M — Quarterly Gross Profit Quarter Ending Gross Profit YoY QoQ March 31, 2015 $0.00 — — March 31, 2014 $0.00 — -100.0% … Read more
Quick Answer Xenetic Biosciences, Inc. reported Operating Income of -$2.83 million for fiscal year 2025. Xenetic Biosciences, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$2.83M +32.6% 2024 -$4.20M +6.9% 2023 -$4.52M +32.8% 2022 -$6.72M -16.9% 2021 -$5.75M +58.8% 2020 -$13.94M -8.2% 2019 -$12.89M -77.1% 2018 -$7.28M -103.9% 2017 -$3.57M … Read more